Brief: Verastem Oncology Provides Update On Ramp 203 Phase 1/2 Clinical Trial
29/12/2025 23:01
Dec 29 (Reuters) - Verastem Inc VSTM.O: VERASTEM ONCOLOGY PROVIDES UPDATE ON RAMP 203 PHASE 1/2 CLINICAL TRIAL FOR ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER VERASTEM INC - DISCONTINUES RAMP 203 TRIAL FOR KRAS G12C-MUTATED NSCLC Source text: ID:nBw5MMk2ha Further company coverage: VSTM.O ((Reuters.Briefs@thomsonreuters.com;))